Market Overview

How Incyte Just Became A Major M&A Target

Share:
How Incyte Just Became A Major M&A Target
Related INCY
Benzinga's Daily Biotech Pulse: SIGA Rallies On FDA Panel Backing, Rigel And Gilead React To Earnings
Syros Takes The Road Less Traveled In Gene Control, Awaits Windfall From Diverse Indications
Related GILD
Gilead, Match Group, Biotech, Ethereum: 'Fast Money' Picks For May 14
55 Biggest Movers From Yesterday
Gilead: Where's The Next Catalyst? (Seeking Alpha)

Incyte Corporation (NASDAQ: INCY) shares are up more than 4.7 percent Thursday following three new analyst notes focusing on new data from Gilead Sciences, Inc. (NASDAQ: GILD)’s SIMPLIFY 1 and 2 Phase III studies on patients with myelofibrosis (MF).

Leerink analyst Michael Schmidt believes the results likely mean a dead end for Gilead.

“Results from both trials are disappointing, in our view making it highly unlikely that GILD would be able to obtain regulatory approval,” Schmidt explains.

However, Gilead’s loss may be Incyte’s gain.

“We view these results as a positive for INCY given Momelotinib is the only late-stage competitor in MF,” Goldman Sachs analyst Terence Flynn writes.

Schmidt takes things one step farther and believes Incyte is now a prime buyout target.

“Removal of uncertainty on the revenue outlook of INCY’s key product [Jakafi] combined with increasing prospects of a repatriation holiday should make the company more attractive from an M&A standpoint,” Schmidt says.

RBC Capital analyst Michael Yee agrees that a buyout is a likely scenario at this point.

Yee believes that Gilead could choose to “go after INCY if their IDO data works in lung cancer… and try to buy it for their oncology assets, leadership, and expertise as well as for Jakafi.”

Incyte shares are down 3.1 percent year-to-date.

Latest Ratings for INCY

DateFirmActionFromTo
Apr 2018JP MorganMaintainsOverweightOverweight
Apr 2018UBSUpgradesNeutralBuy
Apr 2018Morgan StanleyMaintainsOverweightOverweight

View More Analyst Ratings for INCY
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech News Rumors M&A Analyst Ratings General Best of Benzinga

 

Related Articles (GILD + INCY)

View Comments and Join the Discussion!